Metallothioneins (MTs) belong to a group of small cysteine-rich proteins that are ubiquitous throughout all kingdoms. The main function of MTs is scavenging of free radicals and detoxification and homeostating of heavy metals. In humans, 16 genes localized on chromosome 16 have been identified to encode four MT isoforms labelled by numbers (MT-1-MT-4). MT-2, MT-3 and MT-4 proteins are encoded by a single gene. MT-1 comprises many (sub)isoforms. The known active MT-1 genes are MT-1A, -1B, -1E, -1F, -1G, -1H, -1M and -1X. The rest of the MT-1 genes (MT-1C, -1D, -1I, -1J and -1L) are pseudogenes. The expression and localization of individual MT (sub)isoforms and pseudogenes vary at intra-cellular level and in individual tissues. Changes in MT expression are associated with the process of carcinogenesis of various types of human malignancies, or with a more aggressive phenotype and therapeutic resistance. Hence, MT (sub)isoform profiling status could be utilized for diagnostics and therapy of tumour diseases. This review aims on a comprehensive summary of methods for analysis of MTs at (sub)isoforms levels, their expression in single tumour diseases and strategies how this knowledge can be utilized in anticancer therapy.
Introduction
Metallothioneins (MTs) are a group of low molecular mass, cysteinerich proteins that have been found in bacteria, plants, invertebrates and vertebrates (Cai et al., 2014; Ruttkay-Nedecky et al., 2013) . In mammals, the number of amino acids in MTs varies from 61 to 68, from which 20 or 21 are cysteines. Due to high thiol group content, MTs are able to bind 12 monovalent or 7 divalent metal ions and their main functions include maintaining homeostasis of essential metals (Cu and Zn), detoxification of toxic metal ions (Cd) and scavenging free radicals to protect cells against oxidative stress (Klaassen, Liu, & Diwan, 2009) . MT-encoding genes are located on chromosome 16 in a cluster and involve 16 identified genes, from which five are pseudogenes. Two pseudogenes and one MT-like gene are located elsewhere, for details see Table 1 . In humans, four MT isoforms exist, labelled by numbers (MT-1-MT-4). MT-2, MT-3 and MT-4 proteins are encoded by a single gene.
MT-1 comprises many subtypes encoded by a set of 13 MT-1 genes. The known active MT-1 genes are MT-1A, -1B, -1E, -1F, -1G, -1H, -1M and -1X. The rest of the MT-1 genes (MT-1C, -1D, -1I, -1J and -1L) are pseudogenes whose protein product has not been found in humans (Cai et al., 2014; Romero-Isart & Vasak, 2002) . A summary of MT genes, (sub) isoforms, loci and synonyms is shown in Table 1 . The most distinctive differences can be found by comparing MT-1/MT-2 with MT-3, which contains a conserved acidic hexapeptide insert near the C-terminus in the α-domain, additional threonine residue in β-domain and a unique pair of prolines (-TCPCPS-) near the N-terminus in the β-domain, which are essential for biological activity of MT-3, heavy metal binding properties and association with other proteins, which suggest function diversification in various physiological processes (Bogumil et al., 1998) .
MT-1 and -2 are the most widely expressed in the body, occurring predominantly in tissues of kidney, liver, intestine and pancreas. http://dx.doi.org/10. 1016/j.pharmthera.2017.10.004 is found mainly in the brain, but it is also expressed ubiquitously in trace amounts. MT-4 can be detected in epithelia and the maternal deciduae (Wei et al., 2008) . Other differences can be found at the level of the expression and localization of individual MT (sub)isoforms, which vary at intra-cellular level (cytosol, nucleus, mitochondria and lysosomes) and also in individual tissues (Moleirinho et al., 2011; Sharma, Rais, Sandhu, Nel, & Ebadi, 2013; Thirumoorthy et al., 2011) .
Questions regarding the purpose of a high number of MT (sub)isoforms and genes arise with increasing knowledge. Even though differences between affinity to zinc and other metals among single isoforms have been found, as well as susceptibility to antioxidants, these differences do not justify such a high number of isoforms, which, as we anticipate, have to have some further biological importance (Schmidt & Hamer, 1986) . Mammalian MT-1 and MT-2 are transcriptionally induced conserved proteins essential for metal binding. In most mammalian genomes one copy of MT-2, MT-3, MT-4 and multiple copies of MT-1 are present. Specifically, in human genome, 13 MT-1 genes are present, from which 5 are pseudogenes. The highest number of MT-1 copies is found in primate genomes indicating the relatively recent duplication events. The process of gene duplication contributes to phenotypic diversity of living organisms. Novel gene functions arise from mutations altering the sequence of gene product or affecting gene expression. Dynamic changes in tissue expression preference of paralogs with different duplication ages suggest differential contribution of paralogs to specific organ functions. Paralogs are enriched for genes with brain-specific expression and provide evidence for differential forces underlying the preferential emergence of young testis-and liverspecific expressed genes (Guschanski, Warnefors, & Kaessmann, 2017) . Phylogenetic analyses show that MT-1 pseudogenes are derived from functional genes by loss of invariant cysteines and incorporation of aromatic amino acids, and thus accumulation of loss-of-function mutations. The sequence of MT-4 is highly conserved between humans and mice, but it shows the highest divergence in humans with two structurally disrupting polymorphisms. These polymorphisms reach about 30% frequency in African and Asian populations suggesting its non-functionality in some individuals. Some MT-1 duplicates have cellular specificity and some of them are expressed in epithelium. Taken together with similarities between mouse MT-1 and MT-4 structural and metal binding properties it is possible that the high number of MT-1 genes compensates and backs-up the loss of MT-4 gene (Moleirinho et al., 2011) . These findings indicate that the change in expression of single MT genes should be changed in the process of carcinogenesis. In the present review we attempt to summarize up-to-date knowledge on the role of MTs' (sub)isoforms with special emphasis on their roles in malignant diseases (Fig. 1) . Due to the fact that MTs could be helpful as diagnostic and/or prognostic biomarkers in several types of cancers, we also discuss the bioanalytical methods, which enable determination of MTs on (sub)isoform levels. Last but not least, we put our attention on a regulation of MTs by epigenetic processes, whose importance has been evidenced in most malignancies, and on utilization of regulation of MTs to enhance efficiency of cancer therapy, too.
Methods enabling estimation of MT isoforms and (sub)isoforms
It is clear from the above-mentioned facts that MT exists as a mixture of variable forms. This broad heterogeneity leads to the need for development of powerful separation and bioanalytical techniques that enable the study and understanding of the importance of individual MT (sub)isoforms, however, this is still a challenging task. Although there is a high chemical and structural similarity among the isoforms, single MTs are involved in various processes and their expression is dependent on a particular process and tissue. Expression of MTs can be monitored S. Krizkova et al. Pharmacology and Therapeutics 183 (2018) both on nucleic acid level and protein level ( Fig. 2) , i.e. MT protein presence and its modifications, especially metalation, oxidation, acetylation and methylation (Ogra & Suzuki, 1999; Ryvolova et al., 2011) . However, due to the high structural similarity of MTs, current proteomic methods lack the specificity to distinguish all 11 (sub)isoforms. Therefore the most frequent methods for assessment of single MT isoform expression are nucleic-acid based methods, such as in situ hybridization, (Q)-RT-PCR and microarrays Han et al., 2013; Krizkova et al., 2016) . These methods allow for detection of MT gene polymorphisms, regulation of MT expression both based on MT mRNA synthesis and/or degradation by mechanisms of RNA interference either by determination of mRNA, small RNA or non-coding long RNA presence (Yang et al., 2017) . Determination of mRNA does not reflect the amount of MT proteins due to the different mRNA induction and degradation rates as well as RNA-based regulation mechanisms. Thus, determination of both MT protein and mRNA can be useful to obtain complete information (Fig. 2 ). For determination of MT proteins, most of the methods are based on specific chemical properties of MT, especially high thiol group content and heavy metal content, on which are based Ellman's assay, electrochemical and metal-saturation methods, respectively (Bienengraber, Forderkunz, Klein, & Summer, 1995; Dutton, Stephenson, & Klaverkamp, 1993; Krizkova et al., 2009; Ryvolova et al., 2011; Savas, Shaw, & Petering, 1993) . These methods do not allow distinguishing specific MT protein isoforms, even though the differences in redox potential and heavy metal affinity have been found. To detect MT isoforms in biological samples, antibody-based methods such as immunohistochemistry, immunocytochemistry, ELISA and western-blotting are most frequently used. Predominantly, the antibodies recognizing MT-1 + 2 and MT-3 are employed. Due to a high structural similarity between MT-1 and MT-2 isoforms, the development of isoformspecific antibodies is an issue. First the MT-1 and MT-2 isoforms have to be separated or produced by recombinant DNA technology and the obtained antibodies have to be purified from isoform-cross-reactive immunoglobulins (Chan, Pringle, & Cherian, 1992) . Distinguishing of MT-1 (sub)isoforms by using antibodies is even more tricky, due to their high amino acid sequence and structural homology, however commercially available anti-MT-1G and anti-MT-1A antibodies have been used for verification of Q-RT-PCR and RNA interference (Sun, Niu, et al., 2016) . Antibodies specific to MT-3 most frequently recognize the additional C-terminal 6-amino acid-containing domain, which is specific for MT-3 only (Sens, Somji, Garrett, Beall, & Sens, 2001) .
Other methods for analysis of MT on a protein level comprise a broad range of spectroscopic methods hyphenated with different separation techniques. Of them, the most predominant are capillary electrophoresis or high-performance liquid chromatography coupled with mass spectroscopy (CZE-MS or HPLC-MS) (Ryvolova et al., 2011) . Mass spectrometry [electrospray ionization (ESI), matrix assisted laser desorption-ionization (MALDI) and inductively coupled plasma (ICP) ionization techniques] represents the most advanced method in metallomics. These techniques provide essential information about protein identity and structure (ESI, MALDI), and elemental composition (ICP). It has to be also noted that some MS-based studies have succeeded in identifying MT (sub)isoforms in human cells either based on tryptic digests (Alvarez et al., 2012; Shabb, Muhonen, & Mehus, 2017; Wang et al., 2007) , or on unique masses of intact isoforms (Mounicou et al., 2010; Wang et al., 2007) . Moreover, MALDI imaging allows for studying of protein distribution in paraffin-embedded tissue slices or cryosections analogical to histology, with the advantage of detection of multiple or unknown analytes without labelling (Arentz et al., 2017; Norris & Caprioli, 2013; Panderi et al., 2017; Rodrigo et al., 2014) .
MTs can regulate and be distinctly regulated by a number of biological processes
MTs are involved in regulation of numerous processes, among others, cell proliferation and apoptosis and several aspects of the carcinogenesis or inflammation (Theocharis, Margeli, Klijanienko, & Kouraklis, 2004) . Regulative functions of MTs are particularly connected to their protein-protein interactions, metal binding and antioxidant properties. The target proteins for interaction belong to transcription and growth factors, cytokines, extracellular matrix degrading enzymes, apoptosis regulators, stress proteins related to oxidative and radiation damage. Transcription factors such as p53 protein, nuclear factor-κB (NF-κB), esophageal cancer-related gene 4 (ECRG4), specificity protein 1 (Sp1), transcription factor IIIA (TFIIIA), estrogen receptor (ER), Gal4 and tramrack (TTK) interact with MTs and change their function. MTs are also source of zinc or copper and therefore activators of various metalloenzymes, for example matrix metalloproteinases (MMP), carbonic anhydrase, alkaline phosphatase (AP), δ-aminolevulinic acid dehydratase, or superoxide dismutase (SOD). Interaction with MTs was documented also at endocytic low-density lipoprotein receptors (LDLRs), especially megalin and lipoprotein receptor related protein 1 (LRP1) (Krizkova et al., 2012; Zalewska, Trefon, & Milnerowicz, 2014) .
Although MTs show increased expression in various tumours (breast, kidney, lung, nasopharynx, ovary, salivary gland, testes, thyroid and bladder cancers), in certain malignancies such as hepatocellular carcinoma, prostate and colorectal cancer, their down-regulation has been evidenced (Gumulec, Raudenska, Adam, Kizek, & Masarik, 2014; Takahashi, 2015) . Kanda et al. (2009) have suggested that the mechanisms of MT-1G silencing were related to promoter hypermethylation. Furthermore, representative primary gastric cancer having no expression of MT-3-encoding mRNA demonstrated hypermethylation of the MT-3 intron l CpG island (Deng et al., 2003) . The methylated and unmethylated MT-1 promoters are differentially regulated by DNA methyltransferase and methyl-CpG binding proteins, and the suppression of MT promoters by DNA methyltransferase is independent of its enzymatic function (Majumder et al., 2006) . DNA methylation plays an important role in cancer formation by silencing tumour suppressor genes, and thus will be discussed in a separate chapter. Down-regulation of MT synthesis may be also connected with mutation of tumour suppressor genes (Cherian, Jayasurya, & Bay, 2003) . In TP53 mutated cell lines MT was not induced and apoptosis was not initiated after the addition of cadmium or copper (Fan & Cherian, 2002) . Epigenetic inactivation of XAF1 tumour suppressor gene is frequently observed in multiple human cancers. Shin et al. presented evidence that XAF1 plays a critical role in cell-fate decisions under heavy metal induced stress conditions through the mutual antagonism with MT-2A. XAF1 is activated as a transcription target of MTF-1 and destabilizes MT-2A through the interaction-directed lysosomal degradation, whereas it is destabilized by MT-2A under cytostatic stress conditions. XAF1-mediated MT-2A inactivation leads to elevation of free intracellular zinc level and up-and downregulates proteins p53 and XIAP, respectively, to promote apoptosis (Shin et al., 2017) .
MT polymorphisms may increase or decrease the expression efficiency of genes. Highly statistically significant associations were detected between single-nucleotide polymorphisms in core promoter region of MT and Cd, Zn, Cu and Pb levels in prostate cancer tissue (Krzeslak et al., 2013) . MTs are transcriptionally regulated in response to metal ions. A key protein in this process is metal-regulatory factor 1 (MTF1), which binds metal responsive elements located upstream of MT genes. Thus, genetic variation in MTF1 may modulate expression of MT and thereby influence biological management of metals (Adams et al., 2015) .
Connection between epigenetics and MT regulation of human carcinogenesis
Epigenetics, originally defined by Waddington (1942) as 'the causal interactions between genes and their products, which bring the phenotype into being', involves understanding chromatin structure and its impact on gene functions. The information conveyed by epigenetic alterations plays a crucial role in all DNA-based processes, and thus can have profound influence on the development and maintenance of malignant diseases (Dawson & Kouzarides, 2012) . As MTs play an important role in many types for solid tumours and leukemias, the significance of epigenetic modifications of MT genes in cancer cells merits discussion.
Epigenetic alterations due to DNA methylation processes
Genome-wide analyses have shown that DNA methylation is found in long stretches of chromosome regions containing clusters of contiguous CpG islands or gene families. Hypermethylation of various gene clusters has been reported in many cancer types (Esteller, 2007; Jadhav et al., 2015) . Several studies, which have performed methylation analyses, identified de novo hypermethylation of MT promoters associated with consequent MT silencing. In that way, Jadhav et al. (2015) revealed that methylation contributes to repression of MT-1 gene cluster in breast cancer, irrespective of estrogen receptor (ER) status. Noteworthy, they also revealed a negative correlation between invasiveness of ERα+ cells (MCF-7) and MT-1F and MT-1M expression, which thus may play an anti-oncogenic role. A distinct role was identified for MT-3, which is commonly silenced in normal breast tissue and breast-derived cell lines, but can be found in breast cancers tending to poor disease outcome Kmiecik et al., 2015; Zeisig, Koklic, Wiesner, Fichtner, & Sentjurc, 2007) . Interestingly, Somji et al. revealed that treatment of non-tumorigenic MCF-10A cells with demethylation agent Decitabine or histone deacetylase inhibitor, Entinostat, restored the expression of MT-3 (Somji et al., 2010) , suggesting its epigenetic regulation. Comparable phenomenon has been also observed in endometrial cancer cells, in which demethylation agent Azacytidine reactivates expression of MT-1E (Tse et al., 2009 ). Moreover, it was found that promoter of MT-1E was hypermethylated in more than 42% of endometrial carcinoma specimens, but not in normal or hyperplastic endometrial tissue samples.
It is worth noting that epigenetic regulation can act in a locationspecific manner. Peng et al. (2011) have shown that oesophageal carcinomas display high rate of methylation of CpG of MT-3 from − 372 to − 306 from the transcription start site, which was not found in benign specimens. Moreover, they identified a significant correlation between hypermethylation of −127 to − 8 CpG sites with advanced tumour stages and lymph node metastases. Deliberately, we do not mention all studies, as they demonstrate similar results (MT-1F in colon cancer, MT-1 in rat hepatoma, MT-2A in gastric cancer, MT-1M and MT-1G in hepatocellular carcinoma or MT-1G in thyroid cancer; Fu et al., 2013; Ghoshal, Majumder, Li, Dong, & Jacob, 2000; Ji et al., 2014; Pan et al., 2016; Yan et al., 2012) , but overall, it is evident that hypermethylation of specific regions in CpG islands of selected MT genes could be a valuable diagnostic and prognostic marker, warranting further investigation.
One may ask why these events occur. Several factors mechanistically linked with altered methylation have already been identified. During aging a large overlap among hypermethylated genes and tumorigenesis has been identified, and is thus considered as one of the important factors (Klutstein, Nejman, Greenfield, & Cedar, 2016; Kwabi-Addo et al., 2010; Teschendorff et al., 2010) . Clear molecular links with aberrant DNA methylation were found also for exposures to chemical agents (Hutt et al., 2005) or inflammatory processes caused by Helicobacter pylori or hepatitis B virus (Liu et al., 2006; Niwa et al., 2010; Su et al., 2007) despite that there is still a lack of studies showing the straight links between specific exposures and aberrant methylation of MTs genes, which could bring novel insights into carcinogenic processes.
Role of microRNA (miRNA) in post-transcriptional regulation of MTs
MiRNAs belong to a class of short (18-25 nucleotides) noncoding RNAs, involved in RNA interference machinery to regulate post-transcriptional gene expression (Sato, Tsuchiya, Meltzer, & Shimizu, 2011) , contributing to physiological and pathophysiological functions including carcinogenesis (Lu et al., 2005) . Although miRNAs were discovered in 1993 (Lee, Feinbaum, & Ambros, 1993) and till that time they have been intensively investigated, only little is known about relation between miRNA and MT regulation. Zhang et al. (2016) revealed that miR-1246 and miR-1290 are significantly enriched in tumour-initiating cells and play a critical role in regulation of tumour growth and metastasis, particularly through repressing the MT-1G. In gastric cancer, MT-2A was found to be a potential target of miR-23a . A significant inverse correlation between expression of miR-23a and MT-2A was detected in 70% of tumour samples and furthermore, overexpression of miR-23a also greatly reduced both MT-2A protein and mRNA expression levels in gastric epithelial (GES1) cells. Similarly, we have identified a negative inverse correlation between miR-376 and MT-2A in malignant prostate cells (22Rv1) and miR-224 and MT-1A in metastatic prostate (PC-3) cells. It is worth noting that miRNAs obviously directly regulate specific genes encoding MT (sub)isoforms, however further research might be done to fully understand this phenomenon .
5. Regulation and expression of MT (sub)isoforms is distinct across various types of malignant diseases
Complex role of MTs in cancer
Numerous immunohistochemical and gene expression studies have demonstrated that changes in MT expression are associated with the process of carcinogenesis in various types of human malignancies, or are even associated with a more aggressive phenotype and therapeutic resistance, ultimately resulting in a worse prognosis (Gumulec et al., 2014; Pedersen, Larsen, Stoltenberg, & Penkowa, 2009; Thirumoorthy et al., 2011) . Importantly, the change in MT-1/2 protein expression may differ from the change in the expression of single MT isoforms. For instance, MT-1/2 over-expression has been found in cutaneous malignant melanomas in association with poor prognosis (Emri et al., 2013; Sugita, Yamamoto, & Asahi, 2001; Weinlich, 2009) , but it has also been demonstrated that epigenetic down-regulation of MT-1E and MT-1G isoforms might play a role in melanoma progression (Faller et al., 2010; Koga et al., 2009 ). Most likely, some MT isoforms have specific functions in the cells, but the exact mechanisms behind these phenomena still remain unclear. Interestingly, meta-analysis of independent microarray datasets revealed the expression of an inhibitor of apoptosis (BIRC5) and certain MT isoforms (MT-1B, -1E, -1F, -1H, -1X) clustered in various cancers showing a high interconnection between these genes (Choi, Yu, Yoo, & Kim, 2005) . Nevertheless, MT isoform expression pattern in a cancer might reflect the tissue type, differentiation status, proliferative index, the level of inflammation, and perhaps the carcinogenic stimuli and signalling pathways implicated in tumour development (Cherian et al., 2003; Hanada, Sawamura, Hashimoto, Kida, & Naganuma, 1998) . Exploration of changes in expression of particular MT isoforms in various cancers can contribute to better understanding of the process of carcinogenesis and identification of novel therapeutic targets.
To this date numerous studies aiming on MTs in cancer, both in human tumour tissues and cell lines, have been published providing an extensive pool of data. To provide a comprehensive insight into the complicated relation between MTs and cancer, the results showing expression of MTs and their pseudogenes in various tumour tissues are summarized in Table 2 , while the overall summary of results obtained from cell cultures in vitro are summarized in Tables 3-10. As it is obvious from the presented tables, the most data regarding MT (sub)isoforms expression is known for metal exposure, particularly for Cd 2 + and Zn 2 + , which are known MT inducers. Noteworthy, induction of MT genes is not uniform upon metal treatment, as well as it is not within single cell lines even those derived from the same cancer type. A similar trend is seen for other treatments with other metals and cytostatics or inhibitors of cellular processes, natural compounds and/or nanoparticles. Other important fields of studies are focused on regulation of MT genes and studies of cancer-related conditions such as chemoresistance, DNA mutations, RNA interference and hypoxia. Most of the work for MT-1 (sub)isoforms and MT-4 isoform has been done using nucleic acid-based methods due to the lack of reliable antibodies. On the other hand, expression of MT-2A and MT-3 was also studied using immuno-based assays. Overall, based on the data it should be stated that due to the variability of MTs within various tumour types and conditions, a number of MT genes can be identified, whose expression exhibits tumour-related functions, and thus their modulation can reverse the tumour progression. In the next sub-chapters we will describe the most notable findings regarding the MT (sub)isoforms and specific types of malignant diseases.
Prostate cancer
Reduced MT-1/2 protein expression was reported in tissues derived from prostate cancer as compared with benign prostatic hyperplasia (Lee, Wu, Lu, Yang, & Jeng, 2009 ), however, in other studies, an increased expression of MT-1/2 and MT-3 has been found in prostate cancer, and it was even shown to correlate with the histological grade of neoplasm El Sharkawy, Abbas, Badawi, & El Shaer, 2006; . A recent study on 128 patients with prostate cancer demonstrated that high expression of MT-2A protein in cancer cells is associated with a decreased biochemical recurrence-free survival rate (Ma et al., 2015) . The −5 A/G single nucleotide polymorphism (SNP; rs28366003) in the core promoter region of MT-2A is able to affect the expression of the MT-2A gene in prostatic tissue (Krzeslak et al., 2013) . Compared to homozygous common allele carriers, heterozygosity for the G variant is coupled with a significantly increased risk of prostate cancer in a Polish population (Forma et al., 2012) . The expression of MT-2A seems to negatively correlate with Cu, Pb and Ni concentrations in prostate cancer tissues (Krzeslak et al., 2013) . While MT-1A, MT-1E, MT-2A, and MT-3 expressions have been shown in both healthy prostatic tissue and prostate cancer, the expression of MT-1X gene could only be detected in normal prostate Garrett et al., 2000) . Down-regulation of MT-1G by promoter hypermethylation was demonstrated in 29 (24%) of 121 prostate cancer samples, 5 (13%) of 39 high-grade prostatic intraepithelial neoplasms, 3 (10%) of 29 benign prostatic hyperplasia, and 0 (0%) of 13 normal prostate tissue samples without significant differences in methylation frequencies or levels (Henrique et al., 2005) . Methylation levels were found to correlate with tumour stage and were more frequent in prostate cancer that spread beyond the prostate capsule (Henrique et al., 2005) . Low expression of MT-1H due to promoter hypermethylation has been described in prostate cancer with poor prognosis (Han et al., 2013) . In a microRNA microarray study on 50 prostate adenocarcinomas with and without perineural invasion, miR-224 has been identified as the most differently expressed microRNA (Prueitt et al., 2008) . This microRNA has been shown to be expressed by perineural cancer cells and to down-regulate MT expression in these cells (Prueitt et al., 2008) . For a summary of MT (sub)isoform expression studies in human prostate cancer cell lines see Table 3 .
Lung cancer
Increased MT-1/2 protein expression has been demonstrated in 62 (89.9%, n = 69) non-small cell lung cancer (NSCLC) samples as compared to non-malignant lung tissues (NMLT, n = 12) (Werynska, Pula, Muszczynska-Bernhard, Gomulkiewicz, Piotrowska et al., 2013) . Expression of MT-1B, -1F, -1G, -1H and -1X genes were found to be significantly up-regulated, while MT-1E was significantly down-regulated in NSCLC cancer tissues (Werynska, Pula, Muszczynska-Bernhard, Gomulkiewicz, Piotrowska et al., 2013) . Higher MT-1B mRNA expression was associated with squamocellular and adenocarcinoma subtype of NSCLC (Werynska, Pula, Muszczynska-Bernhard, Gomulkiewicz, Piotrowska et al., 2013) , where a review of studies on MT expression in human lung cancer cell lines is shown in Table 4 . Higher MT-1F mRNA expression was associated with larger primary tumour size, with higher grade of malignancy and poor patients' survival (Werynska, Pula, Muszczynska-Bernhard, Gomulkiewicz, Piotrowska, et al., 2013) . In this study, statistically insignificant higher MT-1A mRNA expression was also detected in larger primary tumours, as well as up-regulated MT-2A mRNA that predicted poor prognosis (Werynska, Pula, MuszczynskaBernhard, Gomulkiewicz, Piotrowska, et al., 2013) . In another study, the levels of MT-1A, MT-2A, and MTF-1 expression have been shown to be even lower in lung cancer specimens compared to cancer-surrounding tissues (Liang et al., 2013) . Importantly, MT-1X was identified as a metastasis related gene in NSCLC cell lines in a very recent study . Comparing the expression level of MT-1X in human lung cancer tissues and matched adjacent normal lung tissues, a significant difference could be shown between stages I and IV confirming the prognostic value of MT-1X gene expression in clinical settings . Five SNPs in the MT-1 gene region have been found to be associated with increased risk of lung cancer among non-heavy smokers in a Japanese population (rs7196890 showed the strongest association) and the impact of the polymorphisms decreased with the increasing consumption of cigarettes (Nakane et al., 2015) . Expression of MT-3 has also been investigated in lung cancer, and was found to be significantly up-regulated in NSCLC as compared to NMLT (Werynska, Pula, Muszczynska-Bernhard, Gomulkiewicz, Jethon, et al., 2013) . In addition, compared with NMLT, higher nuclear, but lower cytoplasmic MT-3 expression could be detected in cancer cells (Werynska, Pula, Muszczynska-Bernhard, Gomulkiewicz, Jethon, et al., 2013) . Low cytoplasmic MT-3 expression was associated with larger primary tumour size, nevertheless, lower nuclear MT-3 expression was linked with higher tumour grade, and lower MT-3 mRNA expression seemed to be associated with poor patient outcome (Werynska, Pula, MuszczynskaBernhard, Gomulkiewicz, Jethon, et al., 2013) . From the epigenetic point of view, an overall increase in gene promoter methylation has been reported in association with age and environmental exposure in NMLT (Tsou et al., 2007) . Furthermore, an association between methylation status of MT genes and gender, histology, asbestos exposure, and lymph node involvement was demonstrated in patients with malignant mesothelioma (Tsou et al., 2007) .
Breast cancer
Disequilibrium in zinc homeostasis and high concentration of zinc in breast cancer tissues has been reported (Chandler et al., 2016) . The increased MT gene expression can frequently be detected in breast tumour specimens with predominantly cytoplasmic MT protein expression (see Table 5 for a review of studies on MT expression in human breast cancer cell lines), and it correlates with higher histological grade Bladder cancer MT-1X Bladder cancer Upregulation Somji et al. (2001) Abbreviations: CaP -prostate cancer, NSLC -non-small cell lung cancer, LLC -lung large-cell carcinoma, SCC -squamous cell carcinoma, BCC -basal cell carcinoma, RCC -renal cell carcinoma, APA -adrenocortical aldosterone-producing adenoma, ICC -intrahepatic cholangiocarcinoma, HCC -hepatocellular carcinoma, DLBCL -diffuse large B-cell lymphoma, ABC -activated B-cell, AML -acute myeloid leukaemia, OSCC -oral squamous cell carcinoma. ESCC -oesophageal squamous cell carcinoma, EAC -oesophageal adenocarcinoma, UCEC -uterine corpus endometrial carcinoma, CRC -colorectal cancer.
and significantly lower recurrence-free survival after treatment with adjuvant chemotherapy, but seems to be independent of age, tumour size and estrogen receptor (ER) status (Yap et al., 2009 ). MT-1A, MT-1E, MT-1F, MT-1G, MT-1H, MT-1X and MT-2A but not MT-1B mRNA was detected in invasive ductal breast cancer tissue (IDBC) samples (Jin et al., 2002) . MT-2A, MT-1E, and MT-1F were found to be expressed in both IDBC specimens and their adjacent benign breast tissues, although MT-1F expression seemed to be significantly higher in benign breast tissues compared with the breast cancers; MT-2A was demonstrated as the predominant isoform in both benign and malignant breast tissues (Jin, Bay, Chow, Tan, & Dheen, 2001; Jin et al., 2002) . In another study, higher MT-1F mRNA expression was found to be associated with higher histological grade of breast neoplasm ). MT-2A mRNA and MT protein expression were found to be in association with cancer cell proliferation (Ki-67 immunolabelling) and histological grade (Jin et al., 2002) . In case-control studies, SNPs in MT-2A (rs1580833 in a German population and rs28366003 in a Polish population) showed a positive association with breast cancer risk (Krzeslak et al., 2014; Seibold et al., 2011) . In a further study, significantly higher MT-1E mRNA expression was detected in ER-negative S. Krizkova et al. Pharmacology and Therapeutics 183 (2018) 90-117 breast tumour tissue specimens compared to ER-positive ones (Jin, Bay, Chow, Tan, & Lin, 2000) . Nevertheless, epigenetic repression of MT-1 gene cluster was also demonstrated in breast cancer (Jadhav et al., 2015) . In silico analysis revealed much lower gene expression of this cluster in The Cancer Genome Atlas cohort for ER-positive tumours (Jadhav et al., 2015) . Comparing the methylation of CpG islands in tissues (tumour, healthy breast and blood) from patients with breast cancer revealed that the promoter of MT-1A was methylated above 25% in 18 primary and metastatic tumours, but there was also > 10% methylation of healthy breast tissue in 5 samples suggesting that the methylation process for this gene takes place already in normal breast cells (Piotrowski et al., 2006) . Interestingly, metal induced MT gene expression also seems to be dependent on epigenetic regulation in breast cancer cells, namely on the histone acetylation status of the gene 
Abbreviations: SAE -small airway epithelial cells, THC -delta-9-tetrahydrocannabinol, MGd -motexafin gadolinium, GW1892 -PPAR gamma antagonist.
S. Krizkova et al. Pharmacology and Therapeutics 183 (2018) S. Krizkova et al. Pharmacology and Therapeutics 183 (2018) promoter, which is determined by p53 function (Ostrakhovitch, Olsson, von Hofsten, & Cherian, 2007) . In the presence of mutated p53 the expression of MT-1A and MT-2A is dampened in response to metal, but constitutive MT-3 gene expression is allowed (Ostrakhovitch, Song, & Cherian, 2016) . Sens et al. (2001) showed that MT-3 over-expression was detected in breast cancer samples, and it was found to be associated with high recurrence rate. In another study, however, MT-3 expression has been found to be lower in IDBC specimens compared with non-malignant breast tissues or mastopathies; in addition, the level of MT-3 mRNA was demonstrated to be even lower in breast cancers with lymph node metastasis than in carcinomas without metastasis .
Colorectal cancer
The down-regulation of MT-1/2 expression was revealed in association with colorectal cancer progression, although a relatively high MT content could be detected in colorectal cancers with very poor prognosis (Arriaga et al., 2012; Janssen et al., 2000) . A review of studies on MT expression in colorectal cancer cell lines is shown in Table 6 . Down-regulation of MT-1B (Jansova et al., 2006) (Arriaga et al., 2012) . Radiotherapy seems to be able to induce the expression of MT-1F, MT-1X and MT-2A genes in rectal cancer tissue, however, there is no difference in MT-1/2 protein expression levels between the samples obtained before and after radiotherapy (Szelachowska et al., 2012) . Regarding the mechanism of down-regulation of gene expression, promoter hypermethylation of MT-1G (Arriaga et al., 2012) , and loss of heterozygosity at the MT-1F locus (Yan et al., 2012) have been also identified. Noteworthy, in high microsatellite instability colorectal carcinoma tissues MT-1X T20 (3′UTR, T20 mononucleotide repeat of the MT-1X gene) instability can be more frequently detected as compared to microsatellite stable or low microsatellite instability colorectal cancer cases (97.3% sensitivity and 100% specificity) (Morandi et al., 2012) . Serine peptidase inhibitor, Kazal type 1 (SPINK1) that has been shown to contribute to increased cell proliferation, invasion, soft agar colony formation, and therapy resistance in colon adenocarcinoma cell culture through activation of oncogenic signalling pathways, also seemed to be involved in reduced expression of various MT isoforms in colon cancer cells as SPINK1 knockdown leads to up-regulation of MT-1B, -1E, -1G, -1H, -1L, -1M, -1X, and MT-2A genes in these cells (Tiwari et al., 2015) .
Hepatocellular carcinoma
Compared to the adjacent non-malignant liver, significant Abbreviations: EGF -epithelial growth factor, HRG -heregulin, TBH -t-butyl hydroperoxide, PLU/JARID18 -transcriptional repressor, member of ARID DNA binding proteins, PEITC -phenethyl isothiocyanate, HIPK2 -homeodomain-interacting protein kinase 2.
S. Krizkova et al. Pharmacology and Therapeutics 183 (2018) 90-117 repression of MT-1G and MT-1M due to promoter hypermethylation has been demonstrated in primary hepatocellular carcinomas (Chan et al., 2006; Kanda et al., 2009; Mao et al., 2012) . A recent study confirmed that low MT-1M expression correlates with high alpha-fetoprotein levels and early (< 24 months) tumour recurrence after surgery (Ding & Lu, 2016) . Furthermore, the methylation status of MT-1G and MT-1M promoters detected in serum cell free DNA (liquid biopsy) in patients with hepatocellular carcinoma was also shown to be significantly higher than that in patients with chronic hepatitis B or in normal controls (Ji et al., 2014) . In addition, in carcinoma patients associations have been found between serum MT-1M promoter methylation and tumour size, and between simultaneous MT-1G and MT-1M promoter methylation and higher incidence of vascular invasion or metastasis, respectively (Ji et al., 2014) . Association between hypermethylation of the promoter region of MT-1H and liver cancer with poor clinical outcome has also been reported (Han et al., 2013) . Increased activity of DNA methyltransferase 1 (Dnmt1) might be one of the reasons responsible for down-regulation of MT gene expression in liver cancer (Takata et al., 2013) . Dnmt1 is a direct target of miR-140, and reduced expression of the microRNA-containing ribonucleoprotein complex component DDX20, which is frequently seen in hepatocellular carcinomas, can lead to the impairment of miR-140 function (Takata et al., 2013) . MT-1M is also a target gene of miR-24-3p that is another significantly up-regulated microRNA in liver cancer tissues as compared with non-tumour liver tissues (Dong et al., 2016) . Furthermore, MT gene expression is dependent on DNA binding activity and phosphorylation of CCAAT/enhancer binding protein alpha (C/EBPalpha) in liver cells (Datta et al., 2007) . In hepatocellular carcinoma the phosphorylation of C/EBPalpha is decreased due to suppressed activity of glycogen synthase kinase-3, a downstream effector of PI3K/AKT signalling pathway (Datta et al., 2007) . In a hospital-based case-control study it has been revealed that MT-1 rs8052394, rs964372, and rs8052334 A-G-T haplotype can enhance the carcinogenic effect of smoking on liver, and carriers with this haplotype have higher risk for liver cancer development than the control group (A-C-T, the most common haplotype) (Wong et al., 2013) . Decreased expression of MT-1A, -1E, -1F, -1G, -1H, -1X genes was demonstrated in intrahepatic cholangiocarcinoma tissue samples as compared with normal liver tissues in patients residing in Northeast Thailand, a region with a high prevalence of liver fluke infection (Subrungruang et al., 2013) . Table 7 summarizes studies on expression of MT in hepatic cancer cell lines. Giacomini et al. (2005) Abbreviations: SPINK1 -serine protease inhibitor Kazal-Type 1, AS601245 -JNK inhibitor, TPPS2a -disulfonated meso-tetraphenylporphin, photosensitizer.
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Head and neck cancer
Significantly higher MT-1/2 expression was observed in oral squamous cell carcinoma tissues comparing with oral leukoplakia or normal epithelial tissue samples (Pontes et al., 2009 ). Nevertheless, up-regulation of MT-1F gene expression, but down-regulation of MT-1A, MT-1X, MT-3 and MT-4 gene expressions was detected in carcinoma tissue specimens compared with non-neoplastic oral mucosa (Brazao-Silva et al., 2015) . High MT-1X expression in cancer tissues was restricted to non-metastatic cases, but high MT-3 expression was associated with increased risk of lymph node metastasis (Brazao-Silva et al., 2015) . Furthermore, the low level of MT-1G mRNA in carcinoma tissues correlated with poor prognosis (Brazao-Silva et al., 2015 ). An SNP analysis revealed that MT-1 rs11076161 AA, rs964372 CC, and rs7191779 GC genotypes are protective against oral squamous cell carcinomas, whereas MT-1 rs8052394 A allele is associated with a higher risk to oral cancer development (Zavras, Yoon, Chen, Lin, & Yang, 2011) . Regarding squamous cell laryngeal cancer, the −5 A/G (rs28366003) SNP in the core promoter region of the MT-2A has been shown to be related to a higher cancer risk (Starska, Krzeslak, Forma, Olszewski, Lewy-Trenda et al., 2014) . Moreover, most of the carriers of the minor allele had a higher stage, increased cancer aggressiveness, as defined by a higher total tumour front grading score and diffuse tumour growth (Starska, Krzeslak, Forma, Olszewski, Lewy- Table 7 Summary of MTs (sub)isoforms expression studies in human hepatic cancer cell lines. Up-and down-regulation is related to non-treated cells, if not mentioned otherwise.
Gene
Cell line S. Krizkova et al. Pharmacology and Therapeutics 183 (2018) Trenda et al., 2014). In a further study, a significant association between the rs28366003 SNP in the MT-2A gene and MT-2A mRNA levels was demonstrated in squamous cell laryngeal cancer and non-cancerous laryngeal mucosa samples, and an inverse relation was shown between MT-2A expression and Cd, Zn and Cu content in tissues (Starska, Krzeslak, Forma, Olszewski, Morawiec-Sztandera et al., 2014) . Table 8 summarizes studies on expression of MT in head and neck cancer cell lines.
Oesophageal cancer
Down-regulation of MT-1G, -1M, and MT-3 gene expressions have been detected in oesophageal squamous cell carcinoma tissue samples as compared with non-malignant oesophageal tissues (Kumar, Chatopadhyay, Raziuddin, & Ralhan, 2007; Lee et al., 2011; Oka et al., 2009; Smith et al., 2005) . Importantly, a methylation study on tissue specimens from normal oesophageal mucosae from healthy subjects without carcinogen exposure, normal mucosae from healthy subjects with carcinogen exposure, normal mucosae from cancer patients, and in cancerous mucosae has revealed significantly higher methylation of MT-1M in cancer samples, and in addition, in drinkers and in smokers (Lee et al., 2011; Oka et al., 2009 ). Down-regulation of MT-3 gene expression in oesophageal squamous cell carcinoma seems also to be associated with promoter hypermethylation (Smith et al., 2005) . Nevertheless, a study on DNA methylation profiles in the MT-3 promoter region in oesophageal adenocarcinomas has revealed that in tumour tissues the CpG nucleotides in two regions (from 2139 to −49 and + 296 to +344) were significantly hypermethylated as compared to normal samples, whereas CpG nucleotides from − 372 to − 306 from the transcription start site were highly methylated in both tumour and normal samples (Peng et al., 2011) . Furthermore, the DNA hypermethylation from 2127 to 28 CpG sites was found to be associated with advanced cancer and lymph node metastasis (Peng et al., 2011) .
Recently, up-regulation of the expression of a long non-coding RNA, HNF1A-AS1, has been demonstrated in oesophageal adenocarcinomas relative to their corresponding normal oesophageal tissues, and MT-1E was identified as its downstream target (Yang et al., 2014) .
Tumours of central nervous system
Gene expression studies on glioblastoma tumour specimens revealed an association between high MT-1A, -1B, -1E, -1F, -1H, and MT-3 expression and poor patient survival (Mehrian-Shai et al., 2015) . Moreover, MT-2 protein expression was found to be significantly higher in glioblastoma multiforme tissue samples from the first surgery than in tumour's fragments of the same region but obtained 1 year apart suggesting a dynamic change in MT gene expression with progression in this type of cancer (de Aquino et al., 2016) . Very recently, down-regulation of miR-340 and up-regulation of miR-1293 has been shown in glioblastoma multiforme biopsies (Cosset et al., 2016) . Interestingly, several MT genes (MT-1A, -1E, -1F, -1H, -1X, -2A) were identified as targets of these microRNAs, but it was emphasised that the induced changes in gene expression is influenced by the cellular micro-environment (Cosset et al., 2016) . Down-regulation of MT genes (MT-1L, MT-1G, MT-1E, MT-1X, MT-1B, MT-2A, and MT-3) has been demonstrated as a common event at relapse of ependymoma, however, loss or deletion of the MT genes cluster could not be demonstrated (Peyre et al., 2010) . Methylation of the promoter of MT-3 gene has been supposed, but could not be proved (Peyre et al., 2010) .
Thyroid cancer
Although the up-regulation of MT expression in follicular thyroid carcinoma has been reported in one study (Back et al., 2013) , several data have been published to demonstrate the down-regulation of MT expression in thyroid cancers (both in papillary and follicular thyroid S. Krizkova et al. Pharmacology and Therapeutics 183 (2018) 90-117 Tan et al. (2005) Abbreviations: HNF1A-AS1 -HNF1A antisense RNA 1, TCRP-1 -tongue cancer resistance-associated protein 1, EGCG -(−)-epigallocatechin-3-gallate, green tea catechin.
S. Krizkova et al. Pharmacology and Therapeutics 183 (2018) 90-117 carcinoma, but to a greater extent in papillary carcinoma) compared to normal thyroid tissue (Ferrario et al., 2008; Fu et al., 2013; Huang, De La Chapelle, & Pellegata, 2003) . It has been demonstrated that promoter methylation contributes to MT-1G inactivation in thyroid cancers, and even an association between MT-1G hypermethylation and lymph node metastasis in papillary thyroid cancer patients has been found (Fu et al., 2013; Huang et al., 2003) . Loss of heterozygosity seems to be a remarkably rare mechanism of loss of MT-1G gene function in No treatment Methylation, downregulation Tao, Xu, et al. (2014) Abbreviations: PMA -phorbol-12 myristate-13 acetate, ITF-A -histone deacetylase inhibitor.
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Renal cancer
MT protein expression has been demonstrated in specimens from renal cell carcinoma (RCC) and it was found to be associated with significantly worse prognosis (Nguyen et al., 2000; Tuzel, Kirkali, Yorukoglu, Mungan, & Sade, 2001 ). However, down-regulation of MT-1H (Alkamal et al., 2015; Nguyen et al., 2000; Takahashi et al., 2001) , MT-1G (Alkamal et al., 2015; Takahashi et al., 2001) , MT-2A (Alkamal et al., 2015) , MT-1A, MT-1L and MT-1E (Takahashi et al., 2001 ) have been shown in RCC. In one study, comparing cancer tissue samples to non-malignant tissues from 11 patients with RCC the same level of MT-1E, MT-1F and MT-1X expression, but up-regulation of MT-2A and down-regulation of MT-1A and MT-1G expression were detected in cancer tissue specimens (Nguyen et al., 2000) .
Gastric cancer
Lower MT-2A mRNA and protein expression has been detected in gastric cancer tissue samples comparing with the adjacent normal gastric tissues Pan, Xing, Cui, Li, & Lu, 2013) . In addition, loss of MT-2A expression in gastric cancer seems to be associated with down-regulation of I kappa B-alpha expression, diffuse-and intestinal-type histological subtypes, higher grade, and an advanced clinical stage (Pan, Huang, et al., 2013; Pan, Xing, et al., 2013) . MT-2A is a potential target of miR-23a, and comparing gastric cancer tissue specimens to matched normal tissues an increase in miR-23a expression has been detected and an inverse correlation was found between miR23a and MT-2A expression . Nevertheless, expression of MT-2A can be induced by chemotherapy, and high MT-2A expression in gastric cancer tissue is associated with better response to chemotherapy and prolonged patient survival as compared to those with low MT-2A expression (Pan et al., 2016 ). Furthermore, it seems possible to induce the up-regulation of MT-2A expression by inhibition of histone deacetylase activity in gastric cancer cells (Pan et al., 2016) . Down-regulation of MT-3 gene expression by hypermethylation has also been found in gastric cancers, particularly in p53-negative cases (Deng et al., 2003) .
Bladder cancer
MT-1/2 protein over-expression has been demonstrated in bladder cancer tissues, whereas MT-1/2 expression could not be detected in non-malignant bladder specimens (Somji, Sens, Lamm, Garrett, & Sens, 2001) . In bladder cancer patients a high MT expression in tumour tissues was linked to shorter tumour-specific survival, and increased recurrence rates (Hinkel, Schmidtchen, Palisaar, Noldus, & Pannek, 2008) . Expression of mRNA for the MT-2A and MT-1X genes could be shown in both normal and cancerous bladder tissues, the expression of MT-1E was found to be variable, while expression of MT-1X proved to be up-regulated in cancer as compared to the level of MT-1X mRNA in normal bladder tissue ). In another cohort of patients with bladder cancer the expression of MT-1E has been found to be associated with higher cancer stage (Wu, Siadaty, Berens, Hampton, & Theodorescu, 2008) . Using loss of function analysis, the same research group demonstrated that MT-1E expression contributes to cancer cell migration (Wu et al., 2008) . MT-3 protein expression seems to occur frequently in carcinoma in situ as well as in low-and high-grade urothelial cancer (Somji et al., 2011; Zhou et al., 2006) . In contrast, MT-3 gene is silenced in non-transformed urothelial cells by a mechanism involving histone modification of the MT-3 promoter (Somji et al., 2011) . Abbreviations: BCNU -1,3-bis(2-chloroethyl)-1-nitrosourea, ERK1/2 -extracellular signal-regulated kinase 1, TSHR -thyroid stimulating hormone receptor, TSH -thyroid stimulating hormone, DATS -diallyl trisulphide, DOC -docetaxel, DBC1 -deleted in bladder cancer protein 1, NKK -4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, tobacco carcinogen, STK17A -Serine/Threonine Kinase 17a, RU486 -mifepristone, PRA/B -Progesterone receptor isoform A, CT16 -cancer-testis antigen 16, 8-oxoG -8-oxoguanine.
Endometrium cancer
Loss of MT expression in association with copy number changes has been found to be an early event in the development of uterine corpus endometrial carcinoma, and it was found to be associated with poorer prognosis (Delaney & Stupack, 2016) . Down-regulation of MT-1E gene expression due to promoter hypermethylation could be demonstrated in carcinoma tissue samples, particularly with low ER-alpha expression, as compared with normal endometrial tissues or hyperplasias (Tse et al., 2009 ).
Ovarian cancer
Down-regulation of MT-1L, -1X, and MT-2A gene expression could be revealed in ovarian tissues reflective of low malignant potential/ early cancer onset and possible pre-malignant stages (Mougeot et al., 2006) . However, the absence of MT protein expression in ovarian cancer samples correlated with improved progression-free survival in patients treated with adjuvant platinum-based chemotherapy (Woolston et al., 2010) .
Pancreatic cancer
High MT protein expression was detected in pancreas adenocarcinoma tissues compared with pancreatic serous cystadenoma or healthy pancreatic tissue samples (Sliwinska-Mosson, Milnerowicz, Rabczynski, & Milnerowicz, 2009).
Sarcoma and other mesenchymal tumours
Up-regulation of MT-1B, -1E, -1G, -1H, -1L, -1X, and MT-2A gene expression was found in osteosarcoma tissue samples compared with bone biopsies of non-malignant lesions, and three MT isoforms (MT-1E, -1H and MT-1X) were among the 10 most highly up-regulated genes in the osteosarcoma transcriptome (Endo-Munoz, Cumming, Sommerville, Dickinson, & Saunders, 2010 ). An association between MT-1F, -1H, -1X, and MT-2A over-expression in tumour specimens and high metastasis risk has also been observed in patients with high-grade soft tissue sarcoma (Skubitz, Francis, Skubitz, Luo, & Nilbert, 2012) . As mentioned above, the down-regulation of MT-2A expression is a frequent finding in gastric cancer tissues compared to adjacent normal tissue samples Pan, Xing, et al., 2013) . Interestingly, comparing MT-2A expression in tissue specimens of gastrointestinal stromal tumour (GIST) located in the stomach with that in early gastric carcinomas, significantly lower MT-2A mRNA expression and nuclear MT protein expression were found in GIST samples (Soo et al., 2011) .
Haematological malignancies
Up-regulation of MT gene expression has been demonstrated in diffuse large B-cell lymphoma (DLBCL) with poor prognosis, including activated B-cell and type-3 DLBCL (Poulsen et al., 2006) . In contrast, low to undetectable MT expression has been found in germinal center DLBCL (Poulsen et al., 2006) . Down-regulation of MT-3 gene expression due to promoter methylation has been detected in paediatric acute myeloid leukaemia samples (Tao, Xu, et al., 2014) . Table 9 summarizes studies on expression of MT in human haematological cancer cell lines.
Melanoma and non-melanoma skin cancers
MT-1/2 over-expression has been found in cutaneous malignant melanomas in association with poor prognosis (Emri et al., 2013; Sugita et al., 2001; Weinlich, 2009) . Over-expression of cancer-testis antigen 16 (CT16, PAGE5), a positive regulator of MT-2A has been demonstrated in melanoma metastasis (Nylund et al., 2012) . Nevertheless, MT-1E gene promoter methylation could be revealed in 1 of 17 (6%) of the benign naevi, in 16 of 43 (37%) primary melanoma tumours and in 6 of 13 (46%) melanoma metastases (Faller et al., 2010) . Higher incidence of promoter methylation of MT-1G was also demonstrated in melanomas compared with normal melanocytes and nevi (Koga et al., 2009) . Ectopic over-expression of MT-1E has been demonstrated to increase the sensitivity of melanoma cells to cisplatin-induced apoptosis (Faller et al., 2010) . Low MT-3 protein expression has been demonstrated in normal skin epidermis (Pula et al., 2015; Slusser et al., 2015) . Significantly higher MT-1/2 and MT-3 expression was noted in actinic keratosis and cutaneous squamous cell cancer, as compared with normal skin epidermis, whereas very low levels of MT-3 expression were found in basal cell cancer (Pula et al., 2015; Slusser et al., 2015; Zamirska, Matusiak, Dziegiel, Szybejko-Machaj, & Szepietowski, 2012) . Table 10 summarizes of MT (sub)isoforms expression studies in other human cancer cell lines.
Possibilities of using MT regulation in cancer therapy
The above chapter gives clear evidence that due to their roles and altered expressions in tumours MTs could be targeted to enhance the efficiency of anticancer therapy (Lai, Yip, & Bay, 2011) . Noteworthy, pretreatment with MT inducers can improve chemotherapy tolerance by decreasing the toxic effects of cytostatics in non-target organs (Heger et al., 2016) . On the other hand, this action can result in significant increase of chemoresistance of cancer cells. Thus, specific knowledge on particular roles of MTs has to be obtained. SiRNA silencing of MTs was already published in Lai et al. (2010) and Tarapore, Shu, Guo, and Ho (2011) , where Tarapore et al. used phage Phi29 Motor pRNA as a vehicle to carry siRNA specifically targeted to MT-2A mRNA in ovarian cancers (Tarapore et al., 2011) . Lai et al. (2010) reported that silencing of MT-2A gene by siRNA induces entosis in MCF-7 breast cancer cells. Targeting of a unique mRNA molecule using antisense approaches, based on sequence specificity of double-stranded nucleic acid interactions should, in theory, allow for design of drugs with high specificity for intended targets. Antisense-induced degradation or inhibition of translation of a target mRNA is potentially capable of inhibiting the expression of any target protein (Jason, Koropatnick, & Berg, 2004) . Downregulation of MTs by antisense RNA/DNA is known to inhibit growth of various types of tumour cells. Using this strategy it is possible to inhibit the growth and metastases of breast cancer cells (AbdelMageed & Agrawal, 1997) , leukemia P388 cells, Ehrlich carcinoma, sarcoma 180 (Takeda et al., 1997) and nasopharyngeal cancer cells (Tan, Bay, & Chow, 2005) . Antisense MT mRNA may also induce sensitivity of the cancer cells to cytostatic, either heavy metal-based (Kennette, Collins, Zalups, & Koropatnick, 2005) or others, such as anthracyclines (Wulfing et al., 2007; Yap et al., 2009 ) and kinase inhibitors (Sun, Niu, et al., 2016) .
Cisplatin resistance was inhibited in mouse melanoma cell line by RNA interference using reducible oligo-peptoplex (Lee et al., 2015) . In human cell lines the decrease in basal MT expression by antisense MT mRNA caused increasing of tumour cells' sensitivity to cisplatin (Kennette et al., 2005) . Use of sorafenib, a tyrosine kinase inhibitor, leads to a survival benefit in patients with advanced HCC, but its use is hampered by drug resistance. Targeting MT-1G enhances the anticancer activity of sorafenib in vivo, where suppression of MT-1G expression increased sorafenib sensitivity and negative regulation of ferroptosis in Huh7 and HepG2 cells (Sun, Niu, et al., 2016) .
Another potential role of MT in cancer therapy is its protective action during chemotherapy (Volm, 1998) . Overall, cells with developed resistance to heavy metal-based cytostatics have often increased expression of MTs (Bredel, 2001; Chao, 1996; Naito, Yokomizo, & Koga, 1999; Perez, 1998; Scanlon, Kashanisabet, Tone, & Funato, 1991) . Targeting the MTs with antisense RNA/DNA for reversal of multidrug resistance was successfully proposed (Gosland, Lum, Schimmelpfennig, Baker, & Doukas, 1996) , and could be considered as a pivotal part of personalized cancer therapy.
Although the use of these approaches demonstrates very promising results, we anticipate that further detailed insights into the complex kingdom of MTs may bring higher therapeutic efficiency. For instance, antisense-based therapy can be targeted to multiplex targets, not only one specific sub-isoform. This can enable possible multiplication of therapeutic effects, however a lot of experiments is still required to accelerate these applications.
Conclusions and future outlooks
MTs are crucial biological molecules with a wide range of roles. Particularly, in cancer management, the detailed knowledge of changes in MT expression on sub-isoforms levels allows for a proposal of systems for silencing or restoring their expression with the aim of modulating the efficiency of the treatment protocol and to enhance the patient's outcome. It is worth noting that recent literature shows that the accurate classification of expression pattern of MTs could be also helpful to enhance the diagnostic possibilities and patient's stratification for personalized treatment. Despite fast advances in the field of analytical chemistry, the proper identification of MTs on a protein level is still complicated. Anyway, we believe that such methods will allow for exact understanding of expression of certain subisoforms. This progress will accelerate the description of the biological roles of certain MTs, which are indisputably pivotal for a number of pathophysiological processes.
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